Floatz logo

Dolutegravir

Lipodystrophy

Thomas BenfieldSmall moleculePhase 4 / ApprovedDormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Lipodystrophy cohort.

Asset / SponsorPhaseRating
Efavirenz
Juan A. Arnaiz
Phase 4A
Lamivudine
Thomas Benfield
Phase 4BBB
PRAVASTATIN
Kirby Institute
Phase 4BBB
Retrovir
Kirby Institute
Phase 4BBB
Abacavir
Kirby Institute
Phase 4BBB

View all 36 →

Same molecule, other indications

Dolutegravir is also rated in:

HIV infectious diseaseActive
BBB
Indicative · Phase 4
76 / 100
View asset →
congenital heart diseaseDormant
BB
Indicative · Phase 4
69 / 100
View asset →
fatty liver diseaseActive
BB
Indicative · Phase 4
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →